These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36147357)

  • 1. Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer.
    Li L; Liu T; Liu Q; Mu S; Tao H; Yang X; Li Y; Xiong Q; Wang L; Hu Y
    Front Pharmacol; 2022; 13():967559. PubMed ID: 36147357
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-world efficacy of PD-1/PD-L1 inhibitors in patients with advanced pulmonary neuroendocrine carcinoma: a single-center analysis.
    Zhai W; Yu Y; Wu H; Zhang Q; Chen Y; Yang Y; Fan Y
    Ther Adv Med Oncol; 2024; 16():17588359241288130. PubMed ID: 39410959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety comparison of PD-1 inhibitors
    Yang G; Sun H; Sun N; Huang W; Wang Z; Zhang H; Liu C
    J Thorac Dis; 2022 Dec; 14(12):4925-4937. PubMed ID: 36647464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer].
    Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT
    Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161
    [No Abstract]   [Full Text] [Related]  

  • 5. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy beyond progression in patients with advanced non-small cell lung cancer.
    Ge X; Zhang Z; Zhang S; Yuan F; Zhang F; Yan X; Han X; Ma J; Wang L; Tao H; Li X; Zhi X; Huang Z; Hofman P; Prelaj A; Banna GL; Mutti L; Hu Y; Wang J
    Transl Lung Cancer Res; 2020 Dec; 9(6):2391-2400. PubMed ID: 33489801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective real-world experience of immunotherapy in patients with extensive stage small-cell lung cancer.
    Qiu G; Wang F; Xie X; Liu T; Zeng C; Chen Z; Zhou M; Deng H; Yang Y; Lin X; Xie Z; Sun G; Zhou C; Liu M
    Cancer Med; 2023 Jul; 12(14):14881-14891. PubMed ID: 37462138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approach.
    Zhao J; He Y; Yang X; Tian P; Zeng L; Huang K; Zhao J; Zhou J; Zhu Y; Wang Q; Chen M; Li W; Gao Y; Zhang Y; Xia Y
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 10. Neuron - specific enolase predicts the prognosis in advanced small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors.
    Li L; Zhang Z; Hu Y
    Medicine (Baltimore); 2021 Sep; 100(36):e27029. PubMed ID: 34516493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study.
    Yang J; Zeng R; Zhou J; Luo L; Lyu M; Liu F; Sun X; Zhou L; Wang X; Bao Z; Chen W; Dumoulin DW; Gao B; Xiang Y
    Transl Lung Cancer Res; 2022 Jun; 11(6):1038-1050. PubMed ID: 35832441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuation of immunotherapy beyond progression is beneficial to the survival of advanced non-small-cell lung cancer.
    Cheng Y; Ye Z; Xie Y; Du X; Song S; Ding X; Lin C; Wang B; Li W; Zhang C
    Clin Transl Oncol; 2024 Jun; 26(6):1357-1367. PubMed ID: 38145428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis.
    Shen K; Cui J; Wei Y; Chen X; Liu G; Gao X; Li W; Lu H; Zhan P; Lv T; Lin D
    J Thorac Dis; 2018 Dec; 10(12):6636-6652. PubMed ID: 30746209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
    Zhang S; Li S; Cheng Y
    Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients.
    Zeng R; Liu F; Fang C; Yang J; Luo L; Yue P; Gao B; Dong Y; Xiang Y
    Front Immunol; 2021; 12():724443. PubMed ID: 34777341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of first-line anti-PD-L1 blockades combined with brain radiotherapy for extensive-stage small-cell lung cancer with brain metastasis.
    Ma J; Tian Y; Hao S; Zheng L; Hu W; Zhai X; Meng D; Zhu H
    J Neurooncol; 2022 Sep; 159(3):685-693. PubMed ID: 35976547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal Study of Advanced Non-Small Cell Lung Cancer with Initial Durable Clinical Benefit to Immunotherapy: Strategies for Anti-PD-1/PD-L1 Continuation beyond Progression.
    Pourmir I; Elaidi R; Maaradji Z; De Saint Basile H; Ung M; Ismaili M; Fournier L; Rance B; Gibault L; Ben Dhiab R; Gazeau B; Fabre E
    Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study.
    Deng YY; Zhang XY; Zhu PF; Lu HR; Liu Q; Pan SY; Chen ZL; Yang L
    Front Oncol; 2023; 13():1097911. PubMed ID: 36937443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of sintilimab in combination with chemotherapy for recurrent extensive-stage small cell lung cancer: a real-world retrospective study.
    Wang J; Liang S; Xu L; Kong Y; Seki N; Ganti AK; Neal JW; Li J; Xu F; Li K; Xu Y; Wu L; Chen B
    J Thorac Dis; 2024 Jun; 16(6):3897-3908. PubMed ID: 38983156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors.
    Song P; Zhang J; Shang C; Zhang L
    Sci Rep; 2019 Mar; 9(1):4278. PubMed ID: 30862891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.